Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Stereoselective interaction of tolvaptan with amiodarone under racemic metabolic impact by CYP3A5 genotypes in heart failure patients.

European journal of clinical pharmacology - 1 Aug 2022

Akutsu Shunta, Mino Yasuaki, Naito Takafumi, Hoshikawa Kohei, Saotome Masao, Maekawa Yuichiro, Kawakami Junichi

Abstract excerpt

PURPOSE: The diuretic effect of tolvaptan is largely blood level-dependent although it does exhibit interindividual differences according to cytochrome P450 (CYP) 3A5 genotype. This study aimed to investigate the pharmacokinetic relationship between plasma tolvaptan and its monohydroxylate enantiomers and the factors affecting their metabolism in heart failure patients. METHODS: Japanese heart failure patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytochrome P-450 CYP3A
Share to Genotype

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Heart Failure

Share to Immunosuppressive Agents

Source

Identifiers

PMID: 35604424
DOI: 10.1007/s00228-022-03341-y

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Stereoselective interaction of tolvaptan with amiodarone under racemic metabolic impact by CYP3A5 genotypes in heart failure patients.PMID 35604424Read ↗

Impact of CYP3A5 genotype on tolvaptan pharmacokinetics and their relationships with endogenous markers of CYP3A activity and serum sodium level in heart failure patients.Semantic proximity Read ↗

Determinants of steady-state torasemide pharmacokinetics: impact of pharmacogenetic factors, gender and angiotensin II receptor blockers.Semantic proximity Read ↗

Polymorphism of ORM1 is associated with the pharmacokinetics of telmisartan.Semantic proximity Read ↗

Enantioselectivity in the steady-state pharmacokinetics of metoprolol in hypertensive patients.Semantic proximity Read ↗

Clinical implications of variable antiarrhythmic drug metabolism.Semantic proximity Read ↗

Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes.Semantic proximity Read ↗

Population pharmacokinetics of R- and S-carvedilol in Japanese patients with chronic heart failure.Semantic proximity Read ↗

Debrisoquine phenotype and the pharmacokinetics and beta-2 receptor pharmacodynamics of metoprolol and its enantiomers.Semantic proximity Read ↗

Enantioselective pharmacokinetics of tramadol and its three main metabolites; impact of CYP2D6, CYP2B6, and CYP3A4 genotype.Semantic proximity Read ↗

Pharmacogenetic explanation for excessive beta-blockade following timolol eye drops. Potential for oral-ophthalmic drug interaction.Semantic proximity Read ↗

Tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans.Semantic proximity Read ↗

Pharmacokinetics and safety of mavacamten in healthy Chinese participants with different CYP2C19 phenotypes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.